CTMX

CytomX Therapeutics Inc

Add to Watchlist

Advanced Chart

2.385

+0.005(0.210%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.500

Open

2.420

VWAP

2.43

Vol

676.08K

Mkt Cap

375.74M

Low

2.380

Amount

1.64M

EV/EBITDA(TTM)

7.86

Total Shares

77.92M

295.86M

EV/OCF(TTM)

P/S(TTM)

1.39

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

19.10M

-23.95%

16.13M

-51.77%

16.13M

-57.67%

Estimates Revision

The market is revising Downward the revenue expectations for CytomX Therapeutics, Inc. (CTMX) for FY2025, with the revenue forecasts being adjusted by -6.9% over the past three months. During the same period, the stock price has changed by 218.04%.

Revenue Estimates for FY2025

Revise Downward

-6.9%

In Past 3 Month

Stock Price

Go Up

+218.04%

In Past 3 Month

3 Analyst Rating

88.68% Upside

Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 4.50 USD with a low forecast of 3.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

88.68% Upside

Current: 2.385

Low

3.50

Averages

4.50

High

5.00

88.68% Upside

Current: 2.385

Low

3.50

Averages

4.50

High

5.00

H.C. Wainwright

Neutral -> Buy

upgrade

2025-05-15

Reason

H.C. Wainwright

Price Target

2025-05-15

upgrade

Neutral -> Buy

Reason

Piper Sandler

Edward A. Tenthoff

upgrade

2025-05-15

Reason

Piper Sandler

Edward A. Tenthoff

Price Target

2025-05-15

upgrade

Reason

Piper Sandler analyst Edward A. Tenthoff raised the firm's price target on CytomX Therapeutics to $5 from $2.50 and keeps an Overweight rating on the shares after the company reported positive initial Phase I CX-2051 data in 3rd-line+ metastatic colorectal cancer. The results compare favorably to currently approved agents. Importantly, CytomX's masking technology allowed for a clean safety profile with no Grade 4+ TRAEs. If the early efficacy signal holds, Piper expects CytomX will meet with FDA and initiate a potentially registrational Phase II study in the first half of 2026.

Piper Sandler

Joseph Catanzaro

Buy

Maintains

$3.25 → $2.5

2025-04-14

Reason

Piper Sandler

Joseph Catanzaro

Price Target

$3.25 → $2.5

2025-04-14

Maintains

Buy

Reason

Piper Sandler analyst Edward A. Tenthoff assumed coverage of CytomX Therapeutics with an Overweight rating with a price target of $2.50, down from $3.25. The firm notes CytomX is enrolling the 7th cohort in the Phase I dose-escalation study of CX-2051 in metastatic colorectal cancer with initial data in Q2 2025. Clean safety data will validate this masked EpCAM ADC with any efficacy signal including stable disease a positive in lateline CRC patients, adds Piper. CytomX is also conducting Phase I dose-escalation of Probody masked interferon-alpha2b CX-801 i metastatic melanoma with initial PD data in the second half of 2025 and efficacy data in 2026.

HC Wainwright & Co.

Mitchell Kapoor

Hold

Reiterates

n/a

2025-03-07

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

n/a

2025-03-07

Reiterates

Hold

Reason

HC Wainwright & Co.

Mitchell Kapoor

Hold

Reiterates

n/a

2025-01-07

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

n/a

2025-01-07

Reiterates

Hold

Reason

HC Wainwright & Co.

Mitchell Kapoor

Hold

Reiterates

n/a

2024-11-11

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

n/a

2024-11-11

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for CytomX Therapeutics Inc (CTMX.O) is -9.81, compared to its 5-year average forward P/E of 13.60. For a more detailed relative valuation and DCF analysis to assess CytomX Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

13.60

Current PE

-9.81

Overvalued PE

84.18

Undervalued PE

-56.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.81

Current EV/EBITDA

-54.92

Overvalued EV/EBITDA

8.13

Undervalued EV/EBITDA

-11.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

2.82

Current PS

5.38

Overvalued PS

4.74

Undervalued PS

0.91

Financials

Annual

Quarterly

FY2025Q1

YoY :

+22.80%

50.92M

Total Revenue

FY2025Q1

YoY :

+94.06%

22.62M

Operating Profit

FY2025Q1

YoY :

+70.58%

23.53M

Net Income after Tax

FY2025Q1

YoY :

+58.82%

0.27

EPS - Diluted

FY2025Q1

YoY :

-19.11%

-21.16M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-28.68%

-55.26

FCF Margin - %

FY2025Q1

YoY :

+38.91%

46.20

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 359.35% over the last month.

Sold

0-3

Months

220.0K

USD

3-6

Months

47.9K

USD

6-9

Months

0.0

USD

0-12

Months

34.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1199% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

13.0M

Volume

Months

3-6

1,000K

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 359.35% over the last month.

Sold

0-3

Months

220.0K

USD

3-6

Months

47.9K

USD

6-9

Months

0.0

USD

0-12

Months

34.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CTMX News & Events

Events Timeline

2025-05-19 (ET)

2025-05-19

08:11:44

CytomX Therapeutics announces first patient dosed in Phase 1 study of CX-801

2025-05-12 (ET)

2025-05-12

07:24:54

CytomX Therapeutics 76.9M share Secondary priced at $1.30

2025-05-12

06:19:48

CytomX reports results from interim Phase 1 data for CX-2051

News

9.0

07-09Newsfilter

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

3.0

07-06Yahoo Finance

Do CytomX Therapeutics' (NASDAQ:CTMX) Earnings Warrant Your Attention?

2.0

05-28Benzinga

Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday

People Also Watch

Westport Fuel Systems Inc

Logan Ridge Finance Corp

Unicycive Therapeutics Inc

CPI Aerostructures Inc

Manhattan Bridge Capital Inc

FAQ

What is CytomX Therapeutics Inc (CTMX) stock price today?

The current price of CTMX is 2.385 USD — it has increased 0.21 % in the last trading day.

CTMX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CTMX News & Events

Events Timeline

News

People Also Watch

FAQ

What is CytomX Therapeutics Inc (CTMX) stock price today?

What is CytomX Therapeutics Inc (CTMX)'s business?

What is the price predicton of CTMX Stock?

What is CytomX Therapeutics Inc (CTMX)'s revenue for the last quarter?

What is CytomX Therapeutics Inc (CTMX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for CytomX Therapeutics Inc (CTMX)'s fundamentals?

How many employees does CytomX Therapeutics Inc (CTMX). have?

What is CytomX Therapeutics Inc (CTMX) market cap?